Compare JPMorgan Ultra Short Income ETF (JPST) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs TG Therapeutics Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.3 (market cap $42.37B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 5.2× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 47 Days and TG Therapeutics Inc for 16 Days on average.
| JPST | TGTX | |
|---|---|---|
Market Cap | $42.37B | $8.16B |
Volume | 7,889,185 | 1,735,121 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $59.06 |
52-Week Low | $50.22 | $26.94 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.30 with minimal daily movement, showing stability typical of ultra-short bond funds. Technical indicators signal bearish momentum with moving averages in sell territory, though oversold RSI levels suggest potential near-term stabilization. Recent news highlights institutional position adjustments and growing investor interest in cash-alternative ETFs amid rising rate expectations.
The ETF faces headwinds from active management costs and competitive pressure from similar funds, though demand for ultrashort duration assets provides support. Key risks include interest rate sensitivity and fund flow volatility, while institutional ownership changes indicate mixed sentiment among professional investors.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
